ArticleCureus2024
Recurrent Aseptic (Mollaret) Meningitis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mollaret meningitis is a rare form of recurrent, self-resolving, aseptic meningitis with a high rate of return. Although it has been associated with several conditions, herpes simplex virus type 2 (HSV-2) is most common. Diagnosis requires recurrent (>3) episodes of aseptic meningitis as defined by pleocytosis in cerebrospinal fluid (CSF) with negative bacterial cultures. Management is controversial but focuses primarily on supportive care with a potential role for antiviral therapy in both treatment and prevention of recurrence. This case describes a 35-year-old male with fourteen prior episodes of meningitis presenting with a recurrence of symptoms. CSF studies showed an aseptic meningitis due to HSV-2. He was treated with antiviral therapy and ultimately discharged on daily valacyclovir for recurrence prevention. Increased awareness of this condition amongst emergency physicians may help reduce resource utilization and unnecessary antibiotics, while also enhancing appropriate follow-up and prevention of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.